​

Prime Medicine (PRME) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

PRME Stock Forecast

Prime Medicine (PRME) stock forecast, based on 10 Wall Street analysts, predicts a 12-month average price target of $7.50, with a high of $9.00 and a low of $6.00. This represents a 68.54% increase from the last price of $4.45.

$2 $3 $4 $5 $6 $7 $8 $9 High: $9 Avg: $7.5 Low: $6 Last Closed Price: $4.45

PRME Stock Rating

Prime Medicine stock's rating consensus is Buy, based on 10 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 7 Buy (70.00%), 3 Hold (30.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 10 0 3 7 Strong Sell Sell Hold Buy Strong Buy

PRME Price Target Upside V Benchmarks

TypeNameUpside
StockPrime Medicine68.54%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts-24
Avg Price Target-$8.00$7.50
Last Closing Price$4.45$4.45$4.45
Upside/Downside-79.78%68.54%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Nov, 261103--14
Oct, 261103--14
Sep, 261103--14
Aug, 26193--13
Jul, 26193--13
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Aug 25, 2026Keay NakaeChardan Capital$7.00$3.25115.38%57.30%
Aug 18, 2026BMO Capital$9.00$3.05195.08%102.25%
Jun 29, 2026New Street$8.00$3.43133.24%79.78%
Jun 22, 2026Goldman Sachs$6.00$3.2385.76%34.83%
May 07, 2024Maury RaycroftJefferies$15.00$5.40177.78%237.08%
Apr 02, 2024David NierengartenWedbush$12.00$6.3289.87%169.66%
Oct 09, 2023Kostas BiliourisBMO Capital$19.00$8.75117.14%326.97%
Nov 14, 2022Morgan Stanley$23.00$21.128.90%416.85%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Sep 28, 2026JefferiesMarket OutperformMarket Outperformhold
Sep 25, 2026CitigroupMarket OutperformMarket Outperformhold
Aug 18, 2026BMO CapitalOutperformOutperforminitialise
Jul 08, 2026Cowen & Co.BuyBuyhold
Jun 29, 2026H.C. WainwrightNeutralBuyupgrade
Jun 22, 2026CitigroupMarket OutperformMarket Outperformhold
Oct 29, 2025CitigroupNeutralNeutralhold
May 26, 2025CitigroupOutperformNeutraldowngrade
May 20, 2025H.C. WainwrightBuyNeutraldowngrade
May 20, 2025CitigroupOutperformOutperformhold

Financial Forecast

EPS Forecast

$-8 $-7 $-6 $-5 $-4 $-3 $-2 $-1 $0 $1 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.46$-2.18$-1.65$-1.35---
Avg Forecast$-4.18$-1.90$-1.60$-1.22$-1.11$-1.34$-1.31
High Forecast$0.73$-1.69$-1.32$-0.86$-0.02$-0.57$0.23
Low Forecast$-7.45$-2.01$-1.82$-1.61$-1.72$-1.80$-2.33
Surprise %-65.07%14.74%3.13%10.66%---

Revenue Forecast

$0 $13M $26M $39M $52M $65M Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported--$2.98M$4.63M---
Avg Forecast$4.00M$4.44M$11.55M$18.03M$39.16M$6.52M$16.24M
High Forecast$6.41M$7.12M$27.13M$28.87M$62.72M$6.74M$26.01M
Low Forecast$385.42K$428.24K$5.16M$1.74M$3.77M$6.30M$1.56M
Surprise %---74.17%-74.31%---

Net Income Forecast

$-700M $-540M $-380M $-220M $-60M $100M Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-121.82M$-198.13M$-195.88M$-201.14M---
Avg Forecast$-380.25M$-168.36M$-142.97M$-112.21M$-78.92M$-107.79M$-118.93M
High Forecast$66.44M$-153.57M$-120.44M$-77.81M$-1.67M$-52.26M$20.78M
Low Forecast$-677.62M$-183.14M$-165.50M$-146.60M$-156.18M$-163.32M$-211.94M
Surprise %-67.96%17.69%37.01%79.26%---

PRME Forecast FAQ

Is Prime Medicine stock a buy?

Prime Medicine stock has a consensus rating of Buy, based on 10 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 7 Buy, 3 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Prime Medicine is a favorable investment for most analysts.

What is Prime Medicine's price target?

Prime Medicine's price target, set by 10 Wall Street analysts, averages $7.5 over the next 12 months. The price target range spans from $6 at the low end to $9 at the high end, suggesting a potential 68.54% change from the previous closing price of $4.45.

How does Prime Medicine stock forecast compare to its benchmarks?

Prime Medicine's stock forecast shows a 68.54% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Prime Medicine over the past three months?

  • November 2026: 7.14% Strong Buy, 71.43% Buy, 21.43% Hold, 0% Sell, 0% Strong Sell.
  • October 2026: 7.14% Strong Buy, 71.43% Buy, 21.43% Hold, 0% Sell, 0% Strong Sell.
  • September 2026: 7.14% Strong Buy, 71.43% Buy, 21.43% Hold, 0% Sell, 0% Strong Sell.

What is Prime Medicine’s EPS forecast?

Prime Medicine's average annual EPS forecast for its fiscal year ending in December 2026 is $-1.11, marking a -17.78% decrease from the reported $-1.35 in 2025. Estimates for the following years are $-1.34 in 2027, and $-1.31 in 2028.

What is Prime Medicine’s revenue forecast?

Prime Medicine's average annual revenue forecast for its fiscal year ending in December 2026 is $39.16M, reflecting a 745.48% increase from the reported $4.63M in 2025. The forecast for 2027 is $6.52M, and $16.24M for 2028.

What is Prime Medicine’s net income forecast?

Prime Medicine's net income forecast for the fiscal year ending in December 2026 stands at $-78.925M, representing a -60.76% decrease from the reported $-201M in 2025. Projections indicate $-108M in 2027, and $-119M in 2028.